Neural Regeneration Research ›› 2022, Vol. 17 ›› Issue (3): 482-487.doi: 10.4103/1673-5374.320969

Previous Articles     Next Articles

Pentadecapeptide BPC 157 and the central nervous system

Jakša Vukojević1, *, Marija Milavić2, Darko Perović1, Spomenko Ilić1, Andrea Zemba Čilić3, Nataša Đuran4, Sanja Štrbe3, Zoran Zoričić5, Igor Filipčić6, Petrana Brečić4, Sven Seiverth2, Predrag Sikirić1#br#   

  1. 1Department of Pharmacology, Medical School, University of Zagreb, Zagreb, Croatia; 2Department of Pathology, Medical School, University of Zagreb, Zagreb, Croatia; 3University Clinical Hospital Center “Zagreb”, Zagreb, Croatia; 4University Psychiatric Hospital “Vrapče”, Zagreb, Croatia; 5University Clinical Hospital Center “Sestre Milosrdnice”, Zagreb, Croatia; 6Psychiatric Hospital “Sveti Ivan”, Zagreb, Croatia
  • Online:2022-03-15 Published:2021-10-14
  • Contact: Jakša Vukojević, MD, PhD, jaksa.vukojevic@bolnica-vrapce.hr.

PDF

93

Abstract: We reviewed the pleiotropic beneficial effects of the stable gastric pentadecapeptide BPC 157, three very recent demonstrations that may be essential in the gut-brain and brain-gut axis operation, and therapy application in the central nervous system disorders, in particular. Firstly, given in the reperfusion, BPC 157 counteracted bilateral clamping of the common carotid arteries-induced stroke, sustained brain neuronal damages were resolved in rats as well as disturbed memory, locomotion, and coordination. This therapy effect supports particular gene expression in hippocampal tissues that appeared in BPC 157-treated rats. Secondly, there are L-NG-nitro arginine methyl ester (L-NAME)- and haloperidol-induced catalepsy as well as the rat acute and chronic models of ‘positive-like’ schizophrenia symptoms, that BPC 157 counteracted, and resolved the complex relationship of the nitric oxide-system with amphetamine and apomorphine (dopamine agents application), MK-801 (non-competitive antagonist of the N-methyl-D-aspartate receptor) and chronic methamphetamine administration (to induce sensitivity). Thirdly, after rat spinal cord compression, there were advanced healing and functional recovery (counteracted tail paralysis).  Likewise, in BPC 157 therapy, there is specific support for each of these topics: counteracted encephalopathies; alleviated vascular occlusion disturbances (stroke); counteracted dopamine disturbances (dopamine receptors blockade, receptors super sensitivity development, or receptor activation,  over-release, nigrostriatal damage, vesicles depletion), and  nitric oxide-system disturbances (“L-NAME non-responsive, L-arginine responsive,” and “L-NAME responsive, L-arginine responsive”) (schizophrenia therapy); inflammation reduction, nerve recovery in addition to alleviated hemostasis and vessels function after compression (spinal cord injury therapy). Thus, these disturbances may be all resolved within the same agent’s beneficial activity, i.e., the stable gastric pentadecapeptide BPC 157.

Key words: BPC 157, central nervous system, cytoprotection, injury, nitric oxide system, peptide, regeneration